Administration of eribulin,trastuzumab, and pertuzumab every three weeks until disease progression or occurring adverse events difficult to continue.
Sponsors
JBCRG(Japan Breast Cancer Research Group), Sairtama Breast Cancer Clinical Study Group (SBCCSG)
Conditions
First or second line therapy for advanced or recurrent HER2-positive breast cancer patients who have received taxane and trasutuzumab as adjuvant or recurrent therapy.First-Line therapy for metastatic HER2-positive breast cancer.
Phase 2
A study of eribulin in combination with trastuzumab and pertuzumab for advanced or recurrent human epidermal growth factor receptor 2 (HER2)-positive breast cancer
Active, not recruitingJPRN-UMIN000012232
Start: 2013-11-18Target: 48Updated: 2026-06-29
A phase II study of eribulin in combination with trastuzumab and pertuzumab as First-Line therapy for metastatic HER2-positive breast cancer
Active, not recruitingJPRN-UMIN000021585
Start: 2016-03-24Target: 16Updated: 2026-06-29